Just – Evotec Biologics News and Resources

Just – Evotec Biologics, the biologics segment of Evotec SE, has officially opened its J.POD® biologics development and manufacturing facility in Toulouse, France. This marks the company’s first J.POD® site in Europe, which is located on Campus Curie. The new

Just – Evotec Biologics has expanded its strategic partnership with Sandoz to develop and commercially manufacture biosimilars. The expanded agreement, announced on 8 July 2024, includes appropriate remuneration for early scientific validation and further funding tied to achieving development milestones

Evotec SE’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has been selected by the U.S. Department of Defense (DoD) to develop an accelerated monoclonal antibody (mAb) development and manufacturing solution. This initiative is part of the DoD’s Manufacturing Optimization Program